Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive form of liver disease that occurs when there's an accumulation of fat in the liver. MASH, which was formerly known as ...

I have metabolic dysfunction-associated steatohepatitis (MASH), and I have questions about tracking my liver health and the disease’s progression. Bruce Dimmig had symptoms of MASH -- once known as ...

Metabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis (NASH), involves liver fat buildup that triggers inflammation and damage. The name change aims to be more ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) doesn’t always cause obvious symptoms. When symptoms do appear, fatigue and abdominal pain are the most common. MASLD develops when too ...

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy), an ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...